DDX52 and posterior cortical atrophy: Xenografts in the control group were significantly larger (Fig. 3a) and weighed more than those in the DDX52-knockdown group (Fig. 3b), demonstrating that inhibiting DDX52 significantly suppressed PCa tumorigenesis and growth in vivo.